Hollywood Tomorrow
Creators

Peptide Tracker Built by Novice Coder Hits $60,000 in First Month

A 22-year-old college student leveraged development platform Replit to launch a health tracking app, quickly reaching five-figure monthly revenue.

By Tessa Okafor · August 31, 2026 · 1 min read

Published by Hollywood Tomorrow

Creators illustration for Peptide Tracker Built by Novice Coder Hits $60,000 in First Month
Creators illustration for Peptide Tracker Built by Novice Coder Hits $60,000 in First Month

An undergraduate student with zero prior programming background built a mobile application targeting the expanding health and weight-loss medication space, generating $60,000 in revenue during its initial month on the market.

The developer, identified as Cedric, created the utility after immersing himself in the digital communities centered around peptide therapies and GLP-1 treatments, according to details shared by Peter Yang via Replit executive Amol Jain.

To construct the software without formal training, Cedric turned to Replit, a browser-based development environment that assists users in building applications. Despite having no previous exposure to code, he assembled and tested the mobile product directly through the platform.

According to Jain's account reported by Peter Yang, Cedric "wanted to build something that helps anyone track their peptide and GLP-1 intake and learn more about these emerging medications." Following an initial phase of experimentation, the software launched successfully, bringing in $60,000 in revenue within 30 days.

The application has expanded its footprint beyond its initial launch phase. According to the report, the product currently maintains tens of thousands of active users and continues to add daily subscribers.

Why it matters: The app's rapid monetization underscores how accessible development environments are reshaping the solo creator ecosystem. By lowering the technical barrier to entry, modern software platforms allow non-technical entrepreneurs to quickly capitalize on surging consumer trends such as GLP-1 therapies without requiring outside venture backing.

Reported from the originating source.

Share this story

Keep up with the industry

Join the morning memo for a short daily brief.